Expression of Homeobox A9 (HOXA9) in Non- Melanoma Skin Cancer: A Clinical and Immunohistochemical study
Salama, S., Shoeib, M., Shehata, W., Hemida, A. (2021). Expression of Homeobox A9 (HOXA9) in Non- Melanoma Skin Cancer: A Clinical and Immunohistochemical study. EKB Journal Management System, 83(1), 1527-1535. doi: 10.21608/ejhm.2021.171399
Shimaa Kamel Salama; Mohamed A. Shoeib; Wafaa Ahmed Shehata; Aiat Shaban Hemida. "Expression of Homeobox A9 (HOXA9) in Non- Melanoma Skin Cancer: A Clinical and Immunohistochemical study". EKB Journal Management System, 83, 1, 2021, 1527-1535. doi: 10.21608/ejhm.2021.171399
Salama, S., Shoeib, M., Shehata, W., Hemida, A. (2021). 'Expression of Homeobox A9 (HOXA9) in Non- Melanoma Skin Cancer: A Clinical and Immunohistochemical study', EKB Journal Management System, 83(1), pp. 1527-1535. doi: 10.21608/ejhm.2021.171399
Salama, S., Shoeib, M., Shehata, W., Hemida, A. Expression of Homeobox A9 (HOXA9) in Non- Melanoma Skin Cancer: A Clinical and Immunohistochemical study. EKB Journal Management System, 2021; 83(1): 1527-1535. doi: 10.21608/ejhm.2021.171399

Expression of Homeobox A9 (HOXA9) in Non- Melanoma Skin Cancer: A Clinical and Immunohistochemical study

The Egyptian Journal of Hospital Medicine
Article 111, Volume 83, Issue 1, April 2021, Page 1527-1535  XML PDF (702.27 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2021.171399
View on SCiNiTO View on SCiNiTO
Authors
Shimaa Kamel Salama1; Mohamed A. Shoeib1; Wafaa Ahmed Shehata1; Aiat Shaban Hemida2
1Departments of Dermatology, Andrology and STDs Faculty of Medicine, Menoufia University, Egypt
2Departments of Pathology, Faculty of Medicine, Menoufia University, Egypt
Abstract
Background: Homeobox A9 (HOXA9) has been implicated in acute myeloid leukemia and cancer breast but, little is known about HOXA9 expression in non- melanoma skin cancer (NMSC); basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC). Objective: The aim of the current work was to study HOXA9 expression in NMSC by immunohistochemical method.  Patients and Methods: This case-control study included a total of 45 cases with NMSC; 15 BCC and 30 SCC beside 45 age and sex-matched normal apparently healthy controls, selected from Dermatology, Andrology & Sexually transmitted diseases (STDs) Outpatient Clinic, Menoufia University Hospital, during the period December 2018 to June 2020. Clinical evaluation and histopathological evaluation confirmed the diagnosis of SCC and BCC. Results: Expression of HOXA9 in the overlying epidermis was positive in 83.3% of SCC cases with strong intensity in 68% and nucleocytoplasmic localization in 100%. HOXA9 was positive in 60% of BCC cases with mild intensity in 77.8% and nucleocytoplasmic localization in 100%. In control sections, HOXA9 was in all sections (100%) with strong intensity in 77.8%, and nucleocytoplasmic localization in all of them 100%. Regarding tumor islands; expression of HOXA9 was positive in 26 (86.7%) cases of SCC and was positive in 2 (13.3%) of BCC cases. There was significant higher HOXA9 H- score in control skin than NMSC (p < 0.001). Conclusions: It could be concluded that HOXA9 may be implicated in pathogenesis and may represent a target therapy for NMSC.
 
Keywords
Basal cell carcinoma; Squamous cell carcinoma; Homeobox A9
Statistics
Article View: 194
PDF Download: 367